Non-small cell lung cancer stage III

28 trials 12 recruiting MedDRA PT
28 Registered trials
12 Recruiting
19 Unique sponsors
36 Unique IMPs
19 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 19
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Platinum compound 2 substances
Taxane 2 substances
Antimetabolite 2 substances
Antibody-drug conjugate (ADC) 2 substances
Checkpoint inhibitor (PD-L1) 2 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Vinca alkaloid 2 substances
Kinase inhibitor 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Immunosuppressant 1 substance
Monoclonal antibody 1 substance
Topoisomerase II inhibitor 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Monoclonal antibody (human) 1 substance
Phase III: 7 Phase II/III: 1 Phase II: 14 Phase I/II: 2 Phase I: 1 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 28 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 28 trials

Phase III

7 trials
  • AstraZeneca AB Commercial
    OSIMERTINIB
    2022-500860-36-00 1 country 2018 n=10
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    CARBOPLATIN; CISPLATIN; DURVALUMAB; ETOPOSIDE; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMETREXED
    2022-502886-71-00 11 countries 2019 n=485
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; DURVALUMAB; TIRAGOLUMAB
    2022-502480-38-00 11 countries 2020 n=262
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-506696-10-00 12 countries 2024 n=576
    Ended
  • Maia Biotechnology Inc. Commercial
    2-AMINO-9-((2R,4R,5R)-4-HYDROXY-5-(HYDROXYMETHYL) TETRAHYDROFURAN-2-YL)-1,4,5,9-TETRAHYDRO-6H-PURINE-6-THIONE; CEMIPLIMAB; DOCETAXEL; GEMCITABINE; VINORELBINE
    2024-520164-33-00 4 countries 2025 n=105
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    DURVALUMAB
    2023-508773-82-00 7 countries 2025 n=335
    Recruiting
  • ETOP IBCSG Partners Foundation Academic
    CEMIPLIMAB
    2024-519901-36-00 7 countries 2025 n=300
    Recruiting

Phase II/III

1 trial
  • BioNTech SE Commercial
    BISPECIFIC ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR A AND PROGRAMMED DEATH-LIGAND 1; BNT327
    2024-515764-31-00 9 countries 2025 n=726
    Recruiting

Phase II

14 trials
  • AstraZeneca AB Commercial
    CARBOPLATIN; CISPLATIN; OSIMERTINIB; PACLITAXEL; PEMETREXED
    2023-507798-16-00 1 country 2024 n=16
    Ended
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; DURVALUMAB; FALBIKITUG; INFLIXIMAB; MONALIZUMAB; MYCOPHENOLATE MOFETIL; OLECLUMAB; RILVEGOSTOMIG; VOLRUSTOMIG
    2023-508852-21-00 7 countries 2022 n=493
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB
    2023-503756-27-00 2 countries 2022 n=13
    Ended
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial
    DURVALUMAB
    2024-513948-28-00 1 country 2020 n=57
    Ended
  • Incyte Corp. Commercial
    INCB099280
    2022-502716-37-00 3 countries 2023 n=70
    Ended
  • Innate Pharma Commercial
    DURVALUMAB; IPH5201
    2023-507778-42-00 4 countries 2023 n=69
    Recruiting
  • Maia Biotechnology Inc. Commercial
    2-AMINO-9-((2R,4R,5R)-4-HYDROXY-5-(HYDROXYMETHYL) TETRAHYDROFURAN-2-YL)-1,4,5,9-TETRAHYDRO-6H-PURINE-6-THIONE; CEMIPLIMAB
    2023-504595-26-00 4 countries 2023 n=222
    Recruiting
  • AIO-Studien gGmbH Academic
    SACITUZUMAB GOVITECAN; ZIMBERELIMAB
    2024-517561-16-00 1 country n=50
    Pending
  • Fondazione Ricerca Traslazionale Academic
    DURVALUMAB
    2024-520081-65-00 1 country n=75
    Pending
  • Fundacion GECP Academic
    SOTORASIB
    2024-511268-10-00 1 country 2022 n=19
    Ended
  • G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic
    IMP not specified
    2024-519106-12-00 1 country n=33
    Pending
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    CEMIPLIMAB
    2024-517316-29-00 1 country 2025 n=152
    Recruiting
  • Swiss Group for Clinical Cancer Research Academic
    CARBOPLATIN; CISPLATIN; DOCETAXEL; DURVALUMAB; PACLITAXEL; PEMETREXED; VINORELBINE TARTRATE
    2023-504536-18-00 1 country 2024 n=10
    Ended
  • TheraOp gGmbH Academic
    DURVALUMAB
    2023-510506-41-00 1 country 2024 n=100
    Recruiting

Phase I/II

2 trials
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting
  • BioNTech SE Commercial
    BNT324; BNT327
    2024-520238-31-01 4 countries 2026 n=112 Orphan
    Recruiting

Phase I

1 trial

Phase I (Other)

2 trials
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting
  • Transgene Commercial
    IMP not specified
    2024-514001-65-00 1 country n=20
    Pending

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; PEMBROLIZUMAB
    2024-513060-26-00 3 countries 2021 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BioNTech SE Commercial 3 Phase II/III, Phase I/II 3
AstraZeneca AB Commercial 3 Phase II, Phase III 1
F. Hoffmann-La Roche AG Commercial 3 Phase II, Phase III 0
Transgene Commercial 2 Phase I, Phase I (Other) 0
Maia Biotechnology Inc. Commercial 2 Phase II, Phase III 2
ETOP IBCSG Partners Foundation Academic 2 Phase III 2
Systimmune Inc. Commercial 1 Phase I (Other) 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase II 0
Innate Pharma Commercial 1 Phase II 1
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
AIO-Studien gGmbH Academic 1 Phase II 0
Fondazione Ricerca Traslazionale Academic 1 Phase II 0
Fundacion GECP Academic 1 Phase II 0
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic 1 Phase II 0
Intergroupe Francophone De Cancerologie Thoracique Academic 1 Phase II 1
Swiss Group for Clinical Cancer Research Academic 1 Phase II 0
TheraOp gGmbH Academic 1 Phase II 1
New trials by year
2019
1
2020
2
2021
1
2022
3
2023
3
2024
4
2025
6
2026
2
← All indication landscapes